Pharmacy Benefits Management Services Home

Additionally, five patients experienced a serious adverse event in the open-label extension study.22 These included a life-threatening decrease in blood glucose levels, a severe carcinoid tumor of the stomach, brainstem infarction, intracranial aneurysm and trigeminal neuralgia. ................
................